Literature DB >> 21210287

Different CSF β-amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease.

Brit Mollenhauer1, Hermann Esselmann, Sigrun Roeber, Walter J Schulz-Schaeffer, Claudia Trenkwalder, Mirko Bibl, Petra Steinacker, Hans A Kretzschmar, Jens Wiltfang, Markus Otto.   

Abstract

Decreased levels of β-amyloid (Aβ) 1-42 in cerebrospinal fluid (CSF) are characteristic for Alzheimer's disease (AD) and are also evident in Creutzfeldt-Jakob disease (CJD). Aβ plaques are thought to be responsible for this decrease in AD patients, whereas such Aβ plaques are rarely seen in CJD. To investigate the Aβ pattern in brain and CSF of neuropathologically confirmed CJD and AD patients we used an electrophoretic method to investigate Aβ peptide fractions which are not accessible to ELISA and immunohistochemistry. We analyzed Aβ peptides in the CSF of autopsy-confirmed CJD and AD patients and the corresponding brain homogenates using a quantitative urea-based Aβ electrophoresis immunoblot (Aβ-SDS-PAGE/immunoblot).The CSF Aβ1-42 decrease correlated with the brain Aβ load in AD, but not in CJD. There was no difference in the soluble fractions of brain homogenate in AD and CJD. We therefore conclude that different mechanisms in AD and CJD are responsible for the Aβ1-42 decrease in the CSF.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21210287     DOI: 10.1007/s00702-010-0543-z

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  25 in total

1.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

Authors:  Anne M Fagan; Mark A Mintun; Robert H Mach; Sang-Yoon Lee; Carmen S Dence; Aarti R Shah; Gina N LaRossa; Michael L Spinner; William E Klunk; Chester A Mathis; Steven T DeKosky; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

2.  The amyloid deposits in Alzheimer's disease: their nature and pathogenesis.

Authors:  G G Glenner; C W Wong; V Quaranta; E D Eanes
Journal:  Appl Pathol       Date:  1984

3.  Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

Authors:  M Otto; H Esselmann; W Schulz-Shaeffer; M Neumann; A Schröter; P Ratzka; L Cepek; I Zerr; P Steinacker; O Windl; J Kornhuber; H A Kretzschmar; S Poser; J Wiltfang
Journal:  Neurology       Date:  2000-03-14       Impact factor: 9.910

4.  Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities.

Authors:  M Citron; T S Diehl; G Gordon; A L Biere; P Seubert; D J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

5.  Frontal lobe volume, function, and beta-amyloid pathology in a canine model of aging.

Authors:  P Dwight Tapp; Christina T Siwak; Fu Qiang Gao; Jr-Yuan Chiou; Sandra E Black; Elizabeth Head; Bruce A Muggenburg; Carl W Cotman; Norton W Milgram; Min-Ying Su
Journal:  J Neurosci       Date:  2004-09-22       Impact factor: 6.167

6.  Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease.

Authors:  J A Hainfellner; J Wanschitz; K Jellinger; P P Liberski; F Gullotta; H Budka
Journal:  Acta Neuropathol       Date:  1998-08       Impact factor: 17.088

7.  Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules.

Authors:  C Haass; A Y Hung; M G Schlossmacher; T Oltersdorf; D B Teplow; D J Selkoe
Journal:  Ann N Y Acad Sci       Date:  1993-09-24       Impact factor: 5.691

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

Review 9.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

10.  Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy.

Authors:  M Pitschke; R Prior; M Haupt; D Riesner
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

View more
  8 in total

Review 1.  What can biomarkers tell us about cognition in Parkinson's disease?

Authors:  Brit Mollenhauer; Lynn Rochester; Alice Chen-Plotkin; David Brooks
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

2.  Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD.

Authors:  Franc Llorens; Niels Kruse; Matthias Schmitz; Mohsin Shafiq; José Eriton Gomes da Cunha; Nadine Gotzman; Saima Zafar; Katrin Thune; João Ricardo Mendes de Oliveira; Brit Mollenhauer; Inga Zerr
Journal:  J Neurol       Date:  2015-07-11       Impact factor: 4.849

Review 3.  Biomarkers in biological fluids for dementia with Lewy bodies.

Authors:  Sebastian Schade; Brit Mollenhauer
Journal:  Alzheimers Res Ther       Date:  2014-10-16       Impact factor: 6.982

4.  Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and Aβ42 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants.

Authors:  Samir Abu Rumeileh; Francesca Lattanzio; Michelangelo Stanzani Maserati; Romana Rizzi; Sabina Capellari; Piero Parchi
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

5.  Magnetic poly(2-hydroxyethyl methacrylate) microspheres for affinity purification of monospecific anti-p46 kDa/Myo1C antibodies for early diagnosis of multiple sclerosis patients.

Authors:  Daniel Horák; Helena Hlídková; Yurii Kit; Volodymyr Antonyuk; Severyn Myronovsky; Rostyslav Stoika
Journal:  Biosci Rep       Date:  2017-04-28       Impact factor: 3.840

6.  Novel prion mutation (p.Tyr225Cys) in a Korean patient with atypical Creutzfeldt-Jakob disease.

Authors:  Eva Bagyinszky; YoungSoon Yang; Vo Van Giau; Young Chul Youn; Seong Soo A An; SangYun Kim
Journal:  Clin Interv Aging       Date:  2019-08-02       Impact factor: 4.458

7.  Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.

Authors:  Inger van Steenoven; Wiesje M van der Flier; Philip Scheltens; Charlotte E Teunissen; Afina W Lemstra
Journal:  Alzheimers Res Ther       Date:  2019-10-10       Impact factor: 6.982

Review 8.  Glia and alpha-synuclein in neurodegeneration: A complex interaction.

Authors:  Dominik Brück; Gregor K Wenning; Nadia Stefanova; Lisa Fellner
Journal:  Neurobiol Dis       Date:  2015-03-10       Impact factor: 5.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.